These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 25212258)
1. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Patorno E; Patrick AR; Garry EM; Schneeweiss S; Gillet VG; Bartels DB; Masso-Gonzalez E; Seeger JD Diabetologia; 2014 Nov; 57(11):2237-50. PubMed ID: 25212258 [TBL] [Abstract][Full Text] [Related]
2. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Patorno E; Garry EM; Patrick AR; Schneeweiss S; Gillet VG; Zorina O; Bartels DB; Seeger JD Drug Saf; 2015 Mar; 38(3):295-310. PubMed ID: 25761856 [TBL] [Abstract][Full Text] [Related]
3. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data. Bykov K; He M; Franklin JM; Garry EM; Seeger JD; Patorno E Diabetes Obes Metab; 2019 Sep; 21(9):2029-2038. PubMed ID: 31062453 [TBL] [Abstract][Full Text] [Related]
4. Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature. Wu JW; Boudreau DM; Park Y; Simonds NI; Freedman AN Expert Opin Drug Saf; 2014 Aug; 13(8):1071-99. PubMed ID: 24999107 [TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
6. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs. Colditz GA Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. Landman GW; de Bock GH; van Hateren KJ; van Dijk PR; Groenier KH; Gans RO; Houweling ST; Bilo HJ; Kleefstra N PLoS One; 2014; 9(2):e82880. PubMed ID: 24533045 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Giorgino F; Leonardini A; Laviola L Ann N Y Acad Sci; 2013 Apr; 1281(1):36-50. PubMed ID: 23387439 [TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Bergenstal RM; Bailey CJ; Kendall DM Am J Med; 2010 Apr; 123(4):374.e 9 -18. PubMed ID: 20362759 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064 [TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326 [TBL] [Abstract][Full Text] [Related]
12. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108 [TBL] [Abstract][Full Text] [Related]
13. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. Varas-Lorenzo C; Margulis AV; Pladevall M; Riera-Guardia N; Calingaert B; Hazell L; Romio S; Perez-Gutthann S BMC Cardiovasc Disord; 2014 Sep; 14():129. PubMed ID: 25260374 [TBL] [Abstract][Full Text] [Related]
14. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade. Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199 [TBL] [Abstract][Full Text] [Related]
15. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Huang ES; Meigs JB; Singer DE Am J Med; 2001 Dec; 111(8):633-42. PubMed ID: 11755507 [TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular effects and safety of glucose-lowering drugs: current situation]. Masmiquel L Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910 [TBL] [Abstract][Full Text] [Related]
17. Glucose-lowering treatment in cardiovascular and peripheral artery disease. Suades R; Cosentino F; Badimon L Curr Opin Pharmacol; 2018 Apr; 39():86-98. PubMed ID: 29621740 [TBL] [Abstract][Full Text] [Related]
18. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile. Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663 [TBL] [Abstract][Full Text] [Related]
19. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. Chi C; Snaith J; Gunton JE Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214 [TBL] [Abstract][Full Text] [Related]